Oruka Therapeutics, Inc.
Clinical trials sponsored by Oruka Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing novel antibody therapies for inflammatory skin diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug ORKA-002 tested in humans for the first time Results expected Jan 2027 (estimated)
- New psoriasis drug shows promise in Mid-Stage trial Results expected Jun 2027 (estimated) May already have reported ↗
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New psoriasis shot shows promise in early trial
Disease control OngoingThis study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either ORKA-001 or a placebo injection, and doctors measure how much skin clears up after 16 weeks. The goal is to see if ORKA-001 is safe and effecti…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug ORKA-002 tested in humans for the first time
Knowledge-focused OngoingThis Phase 1 trial is the first time ORKA-002 is being tested in humans. It involves 24 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive a single injection of either ORKA-002 or a placebo. The study is not designed to tr…
Phase 1 • Sponsor: Oruka Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC